文献速递消化道肿瘤放疗胸部肿瘤放疗

pT3N0M0食管癌术后辅助治疗:放疗是否优于化疗

Postoperative adjuvant therapy for pT3N0M0 esophageal carcinoma: does radiotherapy offer added benefit beyond chemotherapy?
PubMed 文献 · Radiat Oncol · 2026-07-15

该回顾性研究分析356例接受辅助治疗的pT3N0M0胸段食管鳞癌患者,其中274例接受手术加术后化疗,82例接受手术加术后放化疗。倾向性评分匹配后,两组5年总生存率分别为65.3%与71.4%,5年无病生存率分别为63.3%与70.9%,差异均无统计学意义。结论认为在整体人群中,术后化疗基础上常规加放疗未显示明确生存优势。

要点

  • 匹配后S+POCT与S+POCRT的5年OS为65.3% vs 71.4%,DFS为63.3% vs 70.9%,均无显著差异。
  • 多因素分析显示术后化疗或放化疗均未独立改善OS。
  • 亚组分析仅下段食管肿瘤从S+POCRT获得显著DFS获益,无亚组显示显著OS获益。

核心结论

  • 在整体pT3N0M0胸段食管鳞癌R0切除且未接受新辅助治疗的患者中,术后化疗 alone 与术后放化疗的生存相当。
  • 常规在术后化疗基础上加放疗可能不提供明确生存优势,需前瞻性研究识别可能获益人群。

研究设计与样本

  • 回顾性研究,纳入2009-2020年四川省肿瘤医院1090例TESCC患者,筛选后分析356例接受辅助治疗者。
  • 274例接受手术加术后化疗(S+POCT),82例接受手术加术后放化疗(S+POCRT),采用倾向性评分匹配平衡基线特征。
  • 比较总生存(OS)和无病生存(DFS),采用Cox比例风险模型评估生存预测因素。

主要发现

  • 匹配前S+POCRT组女性更多,有血管或神经侵犯者更可能接受放化疗。
  • 匹配后每组82例,基线特征均衡;整个队列5年OS为70.9%。
  • 匹配队列中5年OS为65.3%(S+POCT)对71.4%(S+POCRT),5年DFS为63.3%对70.9%,均无统计学显著差异。
  • 多因素分析显示术后化疗或放化疗均未独立改善OS。
  • 亚组分析中下段食管肿瘤更可能从S+POCRT获得显著DFS获益,但无亚组显示显著OS获益。

关键数值与推荐

  • 匹配队列5年OS:S+POCT 65.3%,S+POCRT 71.4%。
  • 匹配队列5年DFS:S+POCT 63.3%,S+POCRT 70.9%。
  • 整个队列5年OS为70.9%。

临床怎么用

  • 对于pT3N0M0胸段食管鳞癌R0切除且未接受新辅助治疗的患者,术后单纯化疗可作为与放化疗相当的辅助治疗选择。
  • 不推荐在整体人群中常规于术后化疗基础上加放疗,下段食管肿瘤可考虑个体化评估放疗获益。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 匹配后每组样本量较小(各82例),可能影响统计效能。
  • 需要前瞻性研究进一步验证并识别放疗获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The optimal postoperative adjuvant treatment for pathological T3N0M0 (pT3N0M0) thoracic esophageal squamous cell carcinoma (TESCC) remains unclear. This study evaluated whether adding radiotherapy to postoperative chemotherapy provides an additional survival benefit in these patients. METHODS: We retrospectively reviewed 1,090 TESCC patients treated at Sichuan Cancer Hospital (2009-2020). After applying inclusion and exclusion criteria, 356 patients who received adjuvant therapy were analyzed: 274 underwent surgery plus postoperative chemotherapy (S+POCT) and 82 received surgery plus postoperative chemoradiotherapy (S+POCRT). Propensity score matching balanced baseline characteristics between groups. Overall survival (OS) and disease-free survival (DFS) were compared, and survival predictors were assessed using a Cox proportional hazards model. RESULTS: Before matching, the S+POCRT group had more female patients, and patients with vascular or perineural invasion were more likely to receive chemoradiotherapy. After matching (82 patients per group), baseline characteristics were balanced. The 5-year OS was 70.9% for the entire cohort. In the matched cohort, 5-year OS rates were 65.3% (S+POCT) versus 71.4% (S+POCRT), and 5-year DFS rates were 63.3% versus 70.9%, respectively. No statistically significant differences in OS or DFS were observed between the two groups. Multivariate analysis indicated that neither postoperative chemotherapy nor chemoradiotherapy independently improved OS. In the subgroup analysis, patients with tumors located in the lower third of the esophagus were more likely to derive a significant DFS benefit from S+POCRT but no subgroup showed a statistically significant OS benefit from S+POCRT compared with S+POCT. CONCLUSIONS: For pT3N0M0 TESCC patients undergoing R0 resection without neoadjuvant therapy, postoperative chemotherapy alone provides comparable survival to chemoradiotherapy in the overall retrospective cohort. These findings suggest that the routine addition of postoperative radiotherapy to chemotherapy may not provide a clear survival advantage in the overall pT3N0M0 TESCC population. Further prospective studies are needed to identify patients who may benefit from postoperative radiotherapy. CLINICAL TRIAL NUMBER: Not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yang T, Wang X, Liu J, et al. Postoperative adjuvant therapy for pT3N0M0 esophageal carcinoma: does radiotherapy offer added benefit beyond chemotherapy? Radiat Oncol. 2026. PMID: 42458490. doi:10.1186/s13014-026-02886-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。